

Affibody Medical announces outcome of rights issue

Stockholm, Sweden, February 12, 2026. Affibody Medical AB (publ) ("Affibody" or the "Company") today announced the outcome of the Company's rights issue of approximately SEK 307 million (the "Rights Issue"), for which the subscription period ended on February 10, 2026.

The outcome of the Rights Issue shows that 11,055,014 shares, corresponding to approximately 79 percent of the Rights Issue, have been subscribed with the support of subscription rights. In addition, 2,937,527 shares, corresponding to approximately 21 percent of the Rights Issue, have been subscribed without the support of subscription rights. Hence, the Rights Issue is fully subscribed.

Affibody's main shareholder Patricia Industries, part of Investor AB, had via its subsidiary Duba AB committed to subscribe for its pro rata share, as well as any remaining shares not subscribed for by other shareholders. Duba AB will own approximately 85 percent of the shares in the Company, after the completion of the Rights Issue.

The Rights Issue will provide the Company with approximately SEK 120 million of new liquid funds before deduction of transaction costs. The remaining amount relates to conversion of shareholder loans, including accrued interest.

On January 20, 2026, Affibody announced that the board of directors had resolved on a rights issue of approximately SEK 307 million with authorisation from the general meeting held on May 27, 2025. Through the Rights Issue, the number of shares in Affibody will increase by 13,992,541, from 24,486,948 to 38,479,489 and the share capital will increase with SEK 69,962,705, from SEK 122,434,740 to SEK 192,397,445, corresponding to a dilution effect of approximately 36.4 percent of the total number of shares and votes in the Company.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Disclaimer

This press release contains forward-looking statements. While Affibody considers the projections to be based on reasonable assumptions, forward-looking statements are subject to both known and unknown risks and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

This press release does not constitute or form part of any offer or invitation to purchase or subscribe for any securities. No assurance shall be given in connection with the information in this press release regarding its accuracy or completeness. Investors shall conduct all investment decisions independently.

Contacts (Affibody)

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Attachments

[Affibody Medical announces outcome of rights issue](#)